Results

1–10 of 83 results for hereditary retinal disease

Oral Gildeuretinol Acetate 14 mg Capsules Stalled Stargardt Disease Progression: Updates in the TEASE-3 Study
Michael Gorin, MD, PhD
Annual Meeting Talks
2024
One Year Follow-up in a Phase 1/2 Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa
Benjamin Bakall, MD, PhD
Annual Meeting Talks
2024
BCVA Analysis of Low- or High-Dose MCO-010 Optogenetic Therapy for Retinitis Pigmentosa: FIRST TIME 100-Week TOPLINE Results From a Phase 2b/3 Clinical Trial (RESTORE)
Michael A. Singer, MD
Annual Meeting Talks
2024
Preclinical Evaluation of BGTF-027 (AAV.7m8-L-opsin), a Novel Intravitreal Gene Therapy for the Treatment of Blue Cone Monochromacy
Szilárd Kiss, MD
Annual Meeting Talks
2024
Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Randomized Controlled Multicenter Phase 2 Skyline Trial
Rajiv Anand, MD, FRCS, FASRS
Annual Meeting Talks
2024
Clinical Characterization of Hexokinase 1 (HK1) Mutations Causing Autosomal Dominant Pericentral Retinitis Pigmentosa
Patrick Staropoli, MD
Annual Meeting Talks
2024
Qualitative Analysis of Imaging Features and Predictors of Visual Acuity in ABCA4- and PRPH2-Related Disease
Kenneth C Fan, MD, MBA
Annual Meeting Talks
2024
Safety, Tolerability, and Efficacy of Tinlarebant: 24-Month Primary Outcomes of the Phase 2 Study in Adolescent Patients With Stargardt Disease
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2024
Safety and Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 8 Years and 9 Years
Stephen R. Russell, MD
Annual Meeting Talks
2024
A Multicenter Post-Authorization Safety Study of Patients Treated With Voretigene Neparvovec-rzyl Gene Therapy in the United States: Interim Analysis at 3 Years
Aaron Nagiel, MD, PhD
Annual Meeting Talks
2024